EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity

Abbas Agaimy, Josephine K Dermawan, Florian Haller, Sabine Semrau, Norbert Meidenbauer, Robert Stoehr, Sigurd Lax, Arndt Hartmann, Ying S Zou, Deyin Xing, Lars Tögel, John M Gross und 1 weitere

Virchows Archiv · 2024

DOI: 10.1007/s00428-024-03908-3 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Virchows Archiv, 2024. Verfasst von Abbas Agaimy und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany. abbas.agaimy@uk-erlang…. Hauptthemen laut MEDLINE: Uterine Neoplasms, Mutation, Erb-b2 Receptor Tyrosine Kinases, Sarcoma. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Erlangen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the increasing use of innovative next generation sequencing (NGS) platforms in routine diagnostic and research settings, the genetic landscape of uterine sarcomas has been dynamically evolving during the last two decades. Notably, the majority of recently recognized genotypes in uterine sarcomas represent gene fusions, while recurrent oncogene mutations of diagnostic and/ or therapeutic value have been rare. Recently, a distinctive aggressive uterine sarcoma expressing S100 and SOX10, but otherwise lacking diagnostic morphological, immunophenotypic and molecular features of other uterine malignancies has been presented in a scientific abstract form (USCAP, 2023), but detailed description and delineation of the entity is still missing. We herein describe two high-grade unclassified uterine sarcomas characterized by spindle to round cell morphology and diffuse expression of S100 and SOX10, originating in the uterine body and cervix of 53- and 45-year-old women and carrying an ERBB3 (p.Glu928Gly) and an ERBB2 (p.Val777Leu) mutation, respectively. Both tumors harbored in addition genomic HER2 amplification, ATRX mutation and CDKN2A deletion. Methylation studies revealed a methylome most similar to MPNST-like tumors, but distinct from melanoma, MPNST, clear cell sarcoma, and endometrial stromal sarcoma. Case 1 died of progressive peritoneal metastases after multiple trials of chemotherapy 47 months after diagnosis. Case 2 is a recent case who presented with a cervical mass, which was biopsied. This study defines a novel heretofore unrecognized aggressive uterine sarcoma with unique phenotypic and genotypic features. Given the potential value of targeting HER2, recognizing this tumor type is mandatory for appropriate therapeutic strategies and for better future delineation of the entity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine NeoplasmsMutationErb-b2 Receptor Tyrosine KinasesSarcomaReceptor, ErbB-3SOXE Transcription FactorsFemaleHumansMiddle AgedS100 ProteinsBiomarkers, TumorNeoplasm Grading

Stichwörter der Autor:innen

EGFRMolecular profiling; nerve sheath tumorTargeted therapyTyrosine kinase fusionsUndifferentiated uterine sarcoma

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptor, ErbB-3SOXE Transcription FactorsS100 ProteinsBiomarkers, TumorERBB2 protein, humanSOX10 protein, humanERBB3 protein, human

Autor:innen und Institutionen

  • Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany. abbas.agaimy@uk-erlangen.de.
  • Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg (CCC ER-EMN), Erlangen, Germany. abbas.agaimy@uk-erlangen.de.
  • Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
  • Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg (CCC ER-EMN), Erlangen, Germany.
  • Department of Radiation Oncology, University Hospital, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.

Förderung

  • Universitätsklinikum Erlangen

Zitieren

APA

Agaimy, A., Dermawan, J. K., Haller, F., Semrau, S., Meidenbauer, N., Stoehr, R., Lax, S., Hartmann, A., Zou, Y. S., Xing, D., Tögel, L., Gross, J. M., & Michal, M. (2024). ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity. Virchows Archiv. https://doi.org/10.1007/s00428-024-03908-3

Vancouver

Agaimy A, Dermawan JK, Haller F, Semrau S, Meidenbauer N, Stoehr R, et al. ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity. Virchows Archiv. 2024. doi:10.1007/s00428-024-03908-3

BibTeX
@article{Agaimy2024,
  author = {Agaimy, Abbas and Dermawan, Josephine K and Haller, Florian and Semrau, Sabine and Meidenbauer, Norbert and Stoehr, Robert and Lax, Sigurd and Hartmann, Arndt and Zou, Ying S and Xing, Deyin and Tögel, Lars and Gross, John M and Michal, Michael},
  title = {ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity},
  journal = {Virchows Archiv},
  year = {2024},
  doi = {10.1007/s00428-024-03908-3}
}
Kostenlos starten →